Search research articles
Contact Us
Filters
Showing results (51-60 of 99) with videos related to
Page
of 10
Sort By:
Leukemia Research
|
April 2, 2024
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
Alberto Risueño, Wendy L See, Iryna Bluemmert, et al.
Leukemia Research
|
December 3, 2014
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure
Sylvain Thepot, Simone Boehrer, Valérie Seegers, et al.
Leukemia Research
|
November 8, 2017
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine
Marie Sébert, Rami S Komrokji, Mikkael A Sekeres, et al.
British Journal of Haematology
|
November 12, 2023
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001
Farhad Ravandi, Hartmut Döhner, Andrew H Wei, et al.
American Journal of Hematology
|
June 27, 2015
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities
Anne Wanquet, Thomas Prebet, Céline Berthon, et al.
Blood Advances
|
August 19, 2018
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
Brian Ball, Rami S Komrokji, Lionel Adès, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 14, 2015
Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey
Eun-Ju Lee, B Douglas Smith, Jessica W Merrey, et al.
Oncotarget
|
April 11, 2015
Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
Raynier Devillier, Véronique Mansat-De Mas, Veronique Gelsi-Boyer, et al.
British Journal of Haematology
|
July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
British Journal of Haematology
|
September 22, 2016
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Amer M Zeidan, Amy J Davidoff, Jessica B Long, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 99) with videos related to
Sort By:
Page
of 10
Leukemia Research
|
April 2, 2024
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
Alberto Risueño, Wendy L See, Iryna Bluemmert, et al.
Leukemia Research
|
December 3, 2014
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure
Sylvain Thepot, Simone Boehrer, Valérie Seegers, et al.
Leukemia Research
|
November 8, 2017
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine
Marie Sébert, Rami S Komrokji, Mikkael A Sekeres, et al.
British Journal of Haematology
|
November 12, 2023
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001
Farhad Ravandi, Hartmut Döhner, Andrew H Wei, et al.
American Journal of Hematology
|
June 27, 2015
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities
Anne Wanquet, Thomas Prebet, Céline Berthon, et al.
Blood Advances
|
August 19, 2018
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
Brian Ball, Rami S Komrokji, Lionel Adès, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 14, 2015
Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey
Eun-Ju Lee, B Douglas Smith, Jessica W Merrey, et al.
Oncotarget
|
April 11, 2015
Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
Raynier Devillier, Véronique Mansat-De Mas, Veronique Gelsi-Boyer, et al.
British Journal of Haematology
|
July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
British Journal of Haematology
|
September 22, 2016
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Amer M Zeidan, Amy J Davidoff, Jessica B Long, et al.
Page
of 10